A Fusion Strategy to Overcome the Immunosuppressive Environment of Liver Cancer: Dual-Adjuvant mRNA Vaccine and Next-Generation LNP Delivery System
##1. Immune evasion mechanisms of hepatocellular carcinoma (HCC) and limitations of GPC3 targeting HCC exhibits a highly immunosuppressive tumor microenvironment (TME), making it difficult for conventional peptide or DNA vaccines to elicit sufficient antitumor immune responses. Although the cancer-specific antigen Glypican-3 (GPC3) is a promising target, its low immunogenicity and reliance on a single epitope constitute a critical weakness that fails to prevent tumor immune escape. Overcoming this requires not only enhanced antigenicity but also a system capable of precisely delivering the antigen to immune hubs such as lymph nodes.
##2. L1‑LNP: Lipid engineering to reduce hepatic accumulation and maximize local expression Through ionizable lipid screening, the team optimized L1‑LNP. Unlike the ALC‑0315‑based LNP, which after administration preferentially accumulates in the liver and can cause systemic toxicity, L1‑LNP achieved more than a four‑fold increase in local expression at the injection site while significantly reducing unnecessary hepatic deposition. This minimizes mRNA vaccine adverse effects and provides a technical foundation for concentrating immune responses at the injection site where antigen‑presenting cells (APCs) are densely populated.
##3. HSP70‑C3d dual adjuvant: simultaneous targeting of cellular and humoral immunity The most sophisticated aspect of this work is the design of a fusion mRNA (HGPC3C) that incorporates HSP70 and C3d. The chaperone protein HSP70 enhances antigen presentation, thereby strengthening cell‑mediated immunity (T‑cell responses), while the complement regulator C3d amplifies B‑cell activation and antibody production (humoral immunity). This dual‑adjuvant strategy induces direct tumor cell killing via increased IFN‑γ and IL‑12p70, and concurrently elicits complementary immune responses through anti‑GPC3 antibodies, exerting multifaceted pressure on the tumor.
##4. Why it Matters: Proof of precision medicine that breaks the immunological privilege of liver cancer The significance of this study lies in its ability to overcome the entrenched immunotolerant environment of HCC through two precise engineering strategies (optimized delivery and dual‑pathway activation). Rather than merely increasing antigen levels, the approach awakens both arms of the immune system (T‑cells and B‑cells) while avoiding toxicity, thereby directing a coordinated attack on the tumor. Notably, when combined with immune‑checkpoint inhibition, the regimen achieved a high suppression rate of 78.3%, providing compelling clinical evidence that could offer genuine curative hope for patients with refractory liver cancer.
Glypican-3 (GPC3) is a sought-after immunotherapeutic target for hepatocellular carcinoma (HCC) due to its tumor-specific expression. However, GPC3-derived peptide vaccines suffer from limited epitope coverage and weak immunogenicity. Herein, we developed a dual-adjuvanted GPC3 mRNA vaccine delivered by local-retention lipid nanoparticles (LNPs). Through rational ionizable lipids screening, we engineered L1-based lipid nanoparticles (L1-LNPs) that achieved 4-fold greater local expression than ALC-0315-LNPs with reduced hepatic accumulation. A fusion mRNA construct (HGPC3C) encoding GPC3 flanked by two molecular adjuvants of HSP70 peptide and complement C3d was further designed. Mechanistic analyses suggested that HSP70 was associated with enhanced cellular immune responses, including elevated IFN-γ and IL-12p70, whereas C3d was associated with enhanced humoral immune responses, including increased IL-6 and anti-GPC3 antibody titers, together supporting coordinated activation of both immune arms. In prophylactic models, L1-LNPs/HGPC3C mRNA achieved 80.4% tumor suppression. In therapeutic settings, L1-LNPs/HGPC3C (59.9%) significantly outperformed ALC-0315-LNPs and non-adjuvanted formulations, validating the coordinated advantages of local delivery and dual-adjuvant design. Its combination with PD-L1 blockade further increased suppression to 78.3%, with enhanced CD8
These data present an integrated delivery‑adjuvant design model that simultaneously addresses the two greatest challenges in liver cancer therapy—hepatic toxicity and low immunogenicity. Fine‑tuning of the LNP composition controls biodistribution, and the HSP70/C3d fusion enhances the quality of the immune response, demonstrating that the mRNA platform has evolved from a simple vaccine to an “intelligent anticancer agent,” an exemplary achievement.